Secukinumab for moderate-to-severe hidradenitis suppurativa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective observational study conducted at Peking Union Medical College Hospital that gave secukinumab to adults with Hurley stage II or III hidradenitis suppurativa. Participants had disease for at least six months with at least one draining tunnel or two inflammatory nodules and had inadequate responses to prior treatments. Patients were followed for efficacy and safety outcomes, with clinical assessments and ultrasound used to document lesion changes. The study ran from June 1, 2025, to June 1, 2026, under institutional ethics approval and informed consent procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥18 years
* diagnosis of moderate-to-severe HS with Hurley stage II or III
* Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
* inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors

Exclusion Criteria:

* active infections (e.g., viral hepatitis, active tuberculosis)
* use of other biologics or systemic immunosuppressants within the past three months
* severe organ dysfunction (e.g., hepatic or renal failure)
* any other conditions that might affect study results

Where it's running

• No. 1 Shuai Fu Yuan, Dongcheng District, Beijing
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa

  This trial tests two dosing regimens of secukinumab to see if they can help Chinese adults with moderate to severe hidradenitis suppurativa.

  Recruiting at 10 sites Phase 4 Novartis · Guangzhou, Guangdong and 9 other locations · NCT07489573

• Evaluating secukinumab's effectiveness with surgery for hidradenitis suppurativa

  This study is testing if using secukinumab along with surgery can help people with moderate to severe hidradenitis suppurativa feel better and have fewer problems after surgery.

  Recruiting Peking Union Medical College · Nanjing, Jiangsu · NCT06926192

• Short-term treatment satisfaction with Cosentyx for hidradenitis suppurativa in Saudi Arabia

  This will see if adults in Saudi Arabia with moderate-to-severe hidradenitis suppurativa who start Cosentyx are satisfied with its convenience, safety, and effectiveness after 24 weeks.

  Recruiting at 4 sites Novartis · Riyadh, SAU and 3 other locations · NCT06785779

• Soquelitinib in adults with hidradenitis suppurativa

  This study tests whether oral soquelitinib can help adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting at 9 sites Phase 1 Corvus Pharmaceuticals, Inc. · West Lafayette, Indiana and 10 other locations · NCT07828860

• ORKA-002 versus placebo for moderate-to-severe hidradenitis suppurativa

  A study tests ORKA-002 against placebo in adults with moderate-to-severe hidradenitis suppurativa to see if it helps reduce symptoms.

  Recruiting at 25 sites Phase 2 Oruka Therapeutics, Inc. · Birmingham, Alabama and 24 other locations · NCT07783542

• SPY072 in adults with moderate to severe hidradenitis suppurativa

  This study tests whether SPY072 can help adults with moderate to severe hidradenitis suppurativa when added to their current care, compared with a placebo over 16 weeks.

  Recruiting at 7 sites Phase 2 Spyre Therapeutics, Inc. · Birmingham, Alabama and 33 other locations · NCT07766005

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.